Global Leading Market Research Publisher QYResearch announces the release of its latest report “Algal Plant-based Empty Capsules – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Algal Plant-based Empty Capsules market, including market size, share, demand, industry development status, and forecasts for the next few years.
For pharmaceutical and nutraceutical formulators, traditional gelatin capsules (animal-derived) are unsuitable for vegetarians, vegans, and consumers with religious dietary restrictions. HPMC capsules (plant-derived from wood pulp) address vegetarian needs but lack natural acid resistance. The algal plant-based empty capsule addresses this through marine polysaccharide delivery: capsules made from algal polysaccharides (carrageenan, alginate) or algae-derived extracts, often combined with HPMC, offering natural acid resistance (no enteric coating required) while remaining vegetarian, vegan, and free from animal-derived ingredients. According to QYResearch’s updated model, the global market for Algal Plant-based Empty Capsules was estimated to be worth US$ 55.6 million in 2025 and is projected to reach US$ 87.56 million, growing at a CAGR of 6.8% from 2026 to 2032. Algal plant-based empty capsules are hollow capsules made primarily from algal polysaccharides or algae-derived extracts, often combined with plant-based excipients such as hydroxypropyl methylcellulose (HPMC). These capsules contain no animal-derived ingredients, making them suitable for vegetarians and individuals with allergies to animal proteins. Algal plant-based capsules offer excellent biocompatibility, chemical stability, and acid resistance, safely delivering pharmaceuticals, dietary supplements, probiotics, enzymes, and other functional compounds. Their natural composition and controllable dissolution properties make them widely used in pharmaceutical, nutraceutical, and functional food applications, particularly for oral dosage forms requiring precise release location or delayed release. In 2024, the global production of algal plant-based empty capsules reached 15.4 billion capsules, with an average price of 34 USD per 10,000 capsules.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6098138/algal-plant-based-empty-capsules
1. Technical Architecture: Capsule Sizes and Algal Material Properties
Algal plant-based empty capsules are segmented by size (capacity), determining fill volume and application:
| Capsule Size | Fill Volume (mL) | Typical Applications | Price per 10,000 capsules (USD) | Market Share (Units) |
|---|---|---|---|---|
| 00# | 0.91-0.95 | High-dose pharmaceuticals, probiotics (50B+ CFU) | $36-46 | 15% |
| 0# | 0.68-0.72 | Standard pharmaceuticals, nutraceuticals | $34-42 | 25% |
| 1# | 0.48-0.52 | Probiotics, enzymes, herbal extracts | $32-38 | 30% |
| 2# | 0.36-0.40 | Small-dose pharmaceuticals, pediatric formulations | $30-36 | 15% |
| 3# | 0.27-0.30 | Low-dose APIs, specialty applications | $28-34 | 10% |
| Others (4#, 5#, 0el) | 0.20-1.00 | Custom, veterinary, clinical trials | $26-48 | 5% |
Key technical challenge – natural acid resistance without enteric coating: Algal polysaccharides (alginate, carrageenan) form gels in acidic conditions (gastric pH), protecting contents. Over the past six months, several advancements have emerged:
- Lonza (February 2026) introduced a carrageenan-based algal capsule (Capsugel) with inherent acid resistance (no enteric coating required), protecting probiotics through stomach (2 hours in 0.1N HCl with <10% release), releasing in small intestine (pH 6.8, >90% release in 45 minutes).
- Qingdao Gather Great Ocean Algae Industry Group (March 2026) commercialized an alginate-based capsule with “pH-responsive” gelation (alginate gels at pH <3.5, dissolves at pH >5.5), targeting colon delivery for IBD therapeutics.
- GoCaps GmbH (January 2026) launched an algal-HPMC hybrid capsule with enhanced oxygen barrier (2x HPMC alone), protecting oxygen-sensitive probiotics for 24 months at room temperature.
Industry insight – algal vs. HPMC vs. gelatin capsule comparison:
| Parameter | Algal Plant-based | HPMC Plant-based | Gelatin | Advantage |
|---|---|---|---|---|
| Source | Marine algae (carrageenan, alginate) | Wood pulp/cotton cellulose | Bovine/porcine collagen | Algal: renewable, marine |
| Acid resistance | Natural (alginate/carrageenan gels) | None (requires enteric coating) | None | Algal: inherent protection |
| Vegetarian/Vegan | Yes | Yes | No | Algal/HPMC |
| Moisture content | 5-9% | 3-7% | 13-16% | HPMC (lowest) |
| Oxygen barrier | Good (alginate) | Moderate | Poor | Algal (best) |
| Cost per 1,000 capsules | $3.20-4.60 | $2.80-4.20 | $2.00-3.20 | Gelatin (cheapest) |
2. Market Segmentation: Capsule Size and Application
The Algal Plant-based Empty Capsules market is segmented as below:
Key Players: Lonza (Switzerland/US), Qingdao Gather Great Ocean Algae Industry Group (China), GoCaps GmbH (Germany)
Segment by Capsule Size:
- 1# – Largest segment (30% of 2025 units). Most common for nutraceuticals (probiotics, enzymes).
- 0# – 25% of units. Standard pharmaceutical capsules.
- 00# – 15% of units. High-dose products.
- 2# – 15% of units. Small-dose products.
- 3# – 10% of units. Low-dose specialty.
- Others – 5% of units.
Segment by Application:
- Health Supplements (Nutraceuticals) – Largest segment (55% of revenue). Probiotics, enzymes, herbal supplements, omega-3 oils.
- Pharmaceuticals – 40% of revenue. Acid-sensitive drugs, colon-targeted therapeutics (IBD), gastric-irritant drugs.
- Others – Functional foods, veterinary (5% of revenue).
Typical user case – algal capsule for probiotic survival: A probiotic manufacturer produces 20 billion CFU Lactobacillus acidophilus capsules. HPMC capsules require enteric coating (secondary step) for acid protection. Algal capsules (Lonza) provide inherent acid protection without coating, reducing manufacturing cost by 15% ($0.003 per capsule) and eliminating coating variability. Survival rate: 85% vs. 70% for uncoated HPMC. Annual volume: 100 million capsules → $300,000 savings + superior efficacy.
Exclusive observation – “clean label” advantage: Algal capsules are perceived as “natural” (seaweed-derived) compared to HPMC (semi-synthetic cellulose). Consumers associate “algae” with sustainability and marine origin. Algal capsules command 10-20% price premium over HPMC in premium nutraceutical brands (gummies, probiotics). “Algae-based capsule” labeling appeals to eco-conscious consumers.
3. Regional Dynamics and Algae Sourcing
| Region | Market Share (2025) | Key Drivers |
|---|---|---|
| Asia-Pacific | 45% | Largest algae production (China, Japan, South Korea), domestic manufacturer (Qingdao Gather Great Ocean Algae), cost leadership |
| North America | 30% | Large nutraceutical market, probiotic growth, clean label demand, Lonza leadership |
| Europe | 20% | Strong pharmaceutical industry, sustainability focus, GoCaps (Germany) leadership |
| RoW | 5% | Emerging nutraceuticals (Latin America, Middle East) |
Exclusive observation – “sustainable sourcing” as competitive advantage: Algal capsules are derived from farmed seaweed (carrageenan from red algae, alginate from brown algae). Seaweed farming sequesters carbon, requires no freshwater or fertilizer, and supports coastal communities. Algal capsule manufacturers market “ocean-friendly” and “carbon-negative” claims, appealing to environmentally conscious consumers. Sustainability certification (MSC, ASC) is emerging as a differentiator.
4. Competitive Landscape and Outlook
| Tier | Supplier | Key Strengths | Focus |
|---|---|---|---|
| 1 | Global leader | Lonza (Switzerland/US) | Carrageenan-based capsules (Capsugel), global distribution, R&D, premium pricing (+20-30%) |
| 2 | Chinese specialist | Qingdao Gather Great Ocean Algae Industry Group (China) | Cost leadership (30-50% below Lonza), domestic market, alginate-based capsules |
| 2 | European specialist | GoCaps GmbH (Germany) | Algal-HPMC hybrid, oxygen barrier, niche applications |
Technology roadmap (2027-2030):
- Fermentation-derived algal polysaccharides – Lab-grown carrageenan and alginate (no seaweed harvest), ensuring consistent quality and sustainability. Pilot stage.
- Colonic delivery algal capsules – Alginate capsules with pH-responsive gelation (gastric protection, ileal release) for IBD therapeutics (mesalamine, budesonide). Clinical trials underway.
- Algal capsules for liquid fills – Algal capsules compatible with non-aqueous liquid fills (oils, PEG), expanding application to softgel alternatives.
With 6.8% CAGR and 15.4 billion capsules produced in 2024, the algal plant-based empty capsule market benefits from probiotic growth, vegetarian/vegan trends, and natural acid resistance demand. Key growth drivers: clean label movement, sustainability concerns, and inherent acid protection (no enteric coating). Risks include higher cost vs. HPMC (10-20% premium), limited supplier base (Lonza dominates), and regulatory status (carrageenan safety debates in some markets).
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
